← Back to Analyst Consensus 
ABCL Buy
AbCellera Biologics Inc.
Current Price —
Implied Upside —
Analysts 17
30-Day Momentum
▲ 2 upgrades / ▼ 0 downgrades / 0 reiterations from 2 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 12, 2026 | UBS | initiate | — → Buy | — | 54% |
| Sep 29, 2026 | JP Morgan | initiate | — → Overweight | — | 54% |
| Aug 11, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Aug 6, 2026 | Stifel | maintain | Buy → Buy | — | 53% |
| Aug 6, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | — | 50% |
| Jul 7, 2026 | Benchmark | upgrade | Hold → Buy | — | 54% |
| May 5, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Apr 10, 2026 | Jones Trading | initiate | — → Buy | $11 | 50% |
| Nov 7, 2025 | Leerink Partners | downgrade | Outperform → Market Perform | $4 | 51% |
| Aug 8, 2025 | Stifel | maintain | Buy → Buy | $7 | 53% |
| Jul 14, 2025 | Keybanc | maintain | Overweight → Overweight | $10 | 53% |
| May 16, 2025 | Truist Securities | maintain | Buy → Buy | $10 | 54% |
| May 9, 2025 | Stifel | maintain | Buy → Buy | $8 | 53% |
| Apr 16, 2025 | Keybanc | maintain | Overweight → Overweight | $5 | 53% |
| Mar 3, 2025 | Benchmark | reiterate | Hold → Hold | $0 | 54% |
| Feb 28, 2025 | Stifel | maintain | Buy → Buy | $10 | 53% |
| Jan 8, 2025 | Keybanc | maintain | Overweight → Overweight | $4 | 53% |
| Nov 5, 2024 | Benchmark | reiterate | — → Hold | $0 | 54% |
| Nov 5, 2024 | Stifel | reiterate | Buy → Buy | $12 | 53% |
| Aug 20, 2024 | Benchmark | downgrade | Buy → Hold | $0 | 54% |
| Jul 11, 2024 | Keybanc | maintain | Overweight → Overweight | $5 | 53% |
| May 8, 2024 | Keybanc | maintain | Overweight → Overweight | $7 | 53% |
| Feb 22, 2024 | Benchmark | upgrade | Hold → Buy | $0 | 54% |
| Feb 21, 2024 | Stifel | maintain | Buy → Buy | $17 | 53% |
| Dec 5, 2023 | Keybanc | initiate | — → Overweight | $6 | 53% |
| Aug 31, 2023 | Benchmark | maintain | Buy → Buy | $12 | 54% |
| Aug 4, 2023 | Goldman Sachs | maintain | Buy → Buy | $24 | 54% |
| May 5, 2023 | Credit Suisse | maintain | — → Outperform | $28 | — |
| Feb 28, 2023 | Cowen & Co. | initiate | — → Outperform | $0 | — |
| Feb 22, 2023 | BMO Capital | maintain | — → Outperform | $32 | 53% |
| Feb 22, 2023 | Credit Suisse | reiterate | — → Outperform | $34 | — |
| Jan 6, 2023 | SVB Leerink | maintain | — → Outperform | $18 | — |
| Dec 15, 2022 | Goldman Sachs | initiate | — → Buy | $30 | 54% |
| Nov 16, 2022 | Truist Securities | initiate | — → Buy | $29 | 54% |
| Nov 9, 2022 | SVB Leerink | maintain | — → Outperform | $20 | — |
| Aug 10, 2022 | Credit Suisse | maintain | — → Outperform | $34 | — |
| Jul 26, 2022 | Piper Sandler | maintain | — → Overweight | $22 | 54% |
| May 11, 2022 | Piper Sandler | maintain | — → Overweight | $21 | 54% |
| May 11, 2022 | SVB Leerink | maintain | — → Outperform | $14 | — |
| Feb 25, 2022 | Credit Suisse | maintain | — → Outperform | $40 | — |
| Feb 25, 2022 | SVB Leerink | maintain | — → Outperform | $20 | — |
| Dec 21, 2021 | Benchmark | initiate | — → Buy | $27 | 54% |
| Nov 19, 2021 | Piper Sandler | initiate | — → Overweight | $33 | 54% |
| Aug 13, 2021 | Credit Suisse | maintain | — → Outperform | $49 | — |
| May 14, 2021 | Credit Suisse | maintain | — → Outperform | $51 | — |
| Mar 30, 2021 | Stifel | maintain | — → Buy | $55 | 53% |
| Feb 8, 2021 | SVB Leerink | maintain | — → Outperform | $52 | — |
| Jan 5, 2021 | Berenberg | initiate | — → Buy | $53 | 29% |
| Jan 5, 2021 | SVB Leerink | initiate | — → Outperform | $45 | — |
| Jan 5, 2021 | Credit Suisse | initiate | — → Outperform | $0 | — |
Price Target Trend
May 14, 2026 Oct 25, 2026
EPS Estimates
+1q —
0y —
+1y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days